<DOC>
	<DOCNO>NCT01401062</DOCNO>
	<brief_summary>The purpose study test safety combine fresolimumab local radiotherapy see combination achieve tumor regression .</brief_summary>
	<brief_title>Fresolimumab Radiotherapy Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Biopsyproven breast cancer , metastatic ( persistent recurrent ) . Failed ≥1 line therapy ( endocrine chemotherapy ) metastatic disease . Min . 3 distinct metastatic site , least one measurable lesion least 1 cm large large diameter . Must ≥4 week since follow treatment ( recovered toxicity prior treatment ≤Grade 1 , exclude alopecia ) : major surgery ; radiotherapy ; chemotherapy ( ≥6 week since therapy nitrosourea , mitomycin , monoclonal antibody bevacizumab ) ; immunotherapy ; biotherapy/targeted therapy . &gt; 18 year age . Life expectancy &gt; 6 month . Eastern Cooperative Oncology Group ( ECOG ) status 0 1 . Adequate organ function include : Hemoglobin ≥10.0g/dL , absolute neutrophil count ( ANC ) ≥1,500/mm3 , platelet ≥100,000/mm3 . Hepatic : Serum total bilirubin ≤1.5x upper limit normal ( ULN ) ( Patients Gilbert 's Disease may include total bilirubin ≤3.0mg/dL ) , alanine aminotransferase ( ALT ) , aspartate aminotransferase ( AST ) ≤2.5xULN . If patient know liver metastasis , ALT and/or AST ≤5xULN allow . Renal : creatinine clearance ≥60mL/min . Prothrombin ( PT ) partial thromboplastin time ( PTT ) &lt; ULN . Negative hepatitis virus B C unless consistent prior vaccination prior infection full recovery . Patients childbearing potential must agree use effective contraception study , ≥3 month last treatment . Understand sign write informed consent document . No consent durable power attorney . Second malignancy unless follow curative intent therapy , disease free ≥2 year probability recurrence &lt; 5 % . Curatively treated earlystage squamous cell carcinoma skin , basal cell carcinoma skin , cervical intraepithelial neoplasia ( CIN ) allow . Concurrent cancer therapy . Uncontrolled central nervous system ( CNS ) metastases , meningeal carcinomatosis , malignant seizure , disease cause threaten neurologic compromise ( e.g . unstable vertebral metastasis ) . History ascites pleural effusion , unless successfully treat . Organ transplant , include allogeneic bone marrow transplant . Immunosuppressive therapy include : Systemic corticosteroid therapy , include replacement therapy hypoadrenalism . Inhaled topical corticosteroid allow ( therapy &lt; 5 day limited systemic steroid antiemetic ) ; Cyclosporine A , tacrolimus , sirolimus . Investigational agent within 4 week prior study enrollment ( ≥6 week treatment longacting agent monoclonal antibody ) . Significant uncontrolled medical illness , e.g . congestive heart failure ( CHF ) , myocardial infarction , symptomatic coronary artery disease , significant ventricular arrhythmia within last 6 month , significant pulmonary dysfunction . Patients remote history asthma active mild asthma may participate . Active infection , include unexplained fever ( &gt; 38.5°C ) . Systemic autoimmune disease ( e.g . systemic lupus erythematosus , active rheumatoid arthritis ) . Known allergy component GC1008 . Active thrombophlebitis , thromboembolism , hypercoagulability state , bleeding , anticoagulation therapy ( include anti platelet agent i.e . aspirin , clopidogrel , ticlopidine , dipyridamole , agent induce longacting platelet dysfunction ) . Patients history deep venous thrombosis allow treat , completely resolve , treatment &gt; 4months . Calcium &gt; 11.0mg/dL ( 2.75mmol/L ) unresponsive uncontrolled response standard therapy ( e.g . bisphosphonates ) . Patients , opinion Investigator , significant medical psychosocial problem , include , limited : Other serious nonmalignancyassociated condition may expect limit life expectancy significantly increase risk SAEs ; Conditions , psychiatric , substance abuse , , , opinion Investigator , would preclude informed consent , consistent followup , compliance aspect study ; Pregnant nursing woman .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>metastatic breast cancer</keyword>
	<keyword>TGF-beta</keyword>
	<keyword>fresolimumab</keyword>
	<keyword>monoclonal antibody</keyword>
	<keyword>radiation therapy</keyword>
	<keyword>abscopal response</keyword>
</DOC>